<SEC-DOCUMENT>0001062993-17-000301.txt : 20170120
<SEC-HEADER>0001062993-17-000301.hdr.sgml : 20170120
<ACCEPTANCE-DATETIME>20170120133259
ACCESSION NUMBER:		0001062993-17-000301
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170119
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170120
DATE AS OF CHANGE:		20170120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17538193

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><u>January 19,
2017 </u></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></U><BR></B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD align=center width="33%"><U><B>000-52138 </B></U></TD>
    <TD align=center width="33%"><U><B>20-2000871 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>156 Valleyview Road, Kelowna, BC Canada </B></U></TD>
    <TD align=center width="50%"><U><B>V1X 3M4 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B>(250)
765-6424 </B></P>
<P align=center><B><U>N/A </U><BR></B>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b)) <BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 7.01 </B></TD>
    <TD align=left width="90%"><B>Regulation FD Disclosure
</B></TD></TR></TABLE>
<P align=justify>A copy of the news release announcing that the successful
development and initial trial of the industry&#146;s first zero-sugar cannabinoid /
pterostilbene edible tablet utilizing both Neutrisci&#146;s and Lexaria&#146;s proprietary
and patented technologies is filed as exhibit 99.1 to this current report and is
hereby incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 9.01 </B></TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits </B></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated January 19,
      2017 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE>
<P align=justify>Date: January 19, 2017</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_3></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>LEXARIA AND NEUTRISCI ANNOUNCE SUCCESSFUL CANNABINOID TABLET
<BR>DEVELOPMENT AND POSITIVE RESULTS FROM INITIAL HUMAN <BR></B><B>OBSERVATIONAL
TRIALS.</B></P>
<P align=justify>Kelowna, BC &#150; January 19, 2017 - Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) and NeutriSci International
Inc. (the "Company" or "NeutriSci") (TSX-V: NU, Frankfurt-1N9) are pleased to
announce the successful development and initial trial of the industry&#146;s first
zero-sugar cannabinoid / pterostilbene edible tablet utilizing both Neutrisci&#146;s
and Lexaria&#146;s proprietary and patented technologies.</P>
<P align=justify>Neutrisci&#146;s proprietary pterostilbene tablet formula was used
to produce the world&#146;s first pterostilbene / cannabidiol (CBD) rapid melt edible
product offering the benefits of Lexaria&#146;s patented CBD conjugation technology.
The market-ready tablet offers improvements in taste, rapidity of onset, and
strength of effect due to greater bioavailability, as had been originally
hypothesized. </P>
<P align=justify>After trial batch formulation and manufacturing was completed,
observational human tests supported that the user will experience the effects
faster and last longer while utilizing smaller amounts of cannabinoid than
competing products. The above noted benefits offer manufacturing efficiencies
over competing products, thus potentially increasing comparative
profitability.</P>
<P align=justify>NeutriSci and Lexaria confirm the companies expect to
officially bind the JV agreement to market and commercialize a line of edible
products using CBD derived from full spectrum hemp oil, which is federally legal
in the United States, to be followed by tetrahydrocannabinol (THC) versions
through distribution programs with both existing and planned new strategic
partners. With successful first-stage formulation and human evaluation
completed, the companies expect to conclude a working JV structure as soon as
possible to financially capitalize on this unique opportunity.</P>
<P align=justify>&#147;This joint venture is a demonstration of the rapid innovation
occurring in the cannabis industry,&#148; commented Chris Bunka, CEO of Lexaria
Bioscience. &#147;We are excited to work with NeutriSci; to combine both technology
and form factor to develop healthy cannabinoid products to be sold within
NeutriSci&#146;s international distribution network.&#148; </P>
<P align=justify>&#147;We are very pleased with the results of this product
formulation and observational trial, as the initial results have be invaluable
in helping NeutriSci open dialogue with several of the world&#146;s largest CBD
manufactures and distributors&#148;, commented Glen Rehman, President of NeutriSci
International. &#147;The idea to use our sublingual tablet and form factor to create
a new line of zero-sugar and dose-controlled cannabinoid edible products will
become a reality.&#148; </P>
<P align=justify>Following the recent approvals for recreational use in certain
US states, Industry researchers have reported that the legal cannabis market
could exceed $20 Billion by 2020.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company&#146;s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Company&#146;s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <BR><U>www.lexariabioscience.com</U> </P>
<P align=justify><B>About NeutriSci International Inc.: </B>NeutriSci
specializes in the innovation, production and formulation of nutraceutical
products. Established in 2009, NeutriSci has focused on the development of
several breakthrough nutraceutical products with an initial focus on areas such
as heart and cholesterol health, sleep deprivation therapies, immune defense as
well as men's prostate and sexual health. NeutriSci continues to build strong
relationships and distribution channels for its BluScience&#153; and NeuEnergy&#153;
products with retailers throughout the United States. NeutriSci is focusing
efforts in strengthening sustainable sales models with Convenience, Chain Drug,
and Mass Market and Supermarket retailers.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>FOR FURTHER INFORMATION PLEASE CONTACT: </TD></TR>
  <TR vAlign=top>
    <TD align=left>Lexaria Bioscience Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left>Chairman &amp; CEO </TD></TR>
  <TR vAlign=top>
    <TD align=left>(250) 765-6424 </TD></TR></TABLE>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that the market-ready tablet offers improvements in taste,
rapidity of onset, and strength of effect due to greater bioavailability, that
the user will experience the effects faster and last longer while utilizing
smaller amounts of cannabinoids than competing products, or that any JV
agreement to market and commercialize a line of edible products using CBD
derived from full spectrum hemp oil, or from tetrahydrocannabinol will ever be
entered. Such forward-looking statements are estimates reflecting the Company's
best judgment based upon current information and involve a number of risks and
uncertainties, and there can be no assurance that other factors will not affect
the accuracy of such forward-looking statements. Access to capital, or lack
thereof, is a major risk and there is no assurance that the Company will be able
to raise required working capital. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent applications and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that any
license agreement, corporate activity in the hemp oil sector, or alternative
health businesses will provide any benefit to Lexaria, or that the Company will
experience any growth through participation in these sectors or as a result of
the granted patent. There is no assurance that existing capital is sufficient
for the Company's needs or that it will be able to raise additional capital.
There is no assurance that Lexaria&#146;s technology will deliver any improvement in
taste or bioavailability with any reliability nor across any product category. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp
oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever, nor that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria&rsquo;s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact
be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  Lexaria Energy Foods and ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or prevent any disease.</P>
<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
